Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.

Abstract

BACKGROUND AND AIMS The cellular mechanisms leading to infliximab therapy response in patients with ulcerative colitis (UC) are incompletely known. We therefore investigated early effects of infliximab therapy on monocytes and associated chemokines linked to clinical therapy response in UC patients. METHODS Blood and biopsies were obtained from anti-TNF… (More)
DOI: 10.1093/ecco-jcc/jju008

Topics

1 Figure or Table

Statistics

020406020162017
Citations per Year

Citation Velocity: 15

Averaging 15 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Slides referencing similar topics